Regulation of Angiogenesis
update：2020-06-16
Features
Angiogenesis, i.e., the formation of new capillaries, takes place under pathophysiological conditions including cancers, ocular neovascular diseases and atherosclerosis. Anti-angiogenic drugs have been developed, and are now in clinical use. However, because of side effects due to the damage to vascular endothelial cells, the development of anti-angiogenic drugs with different modalities is anticipated. We have isolated vasohibin-1 (VASH1) as a novel angiogenesis inhibitor expressed by endothelial cells (ECs), and vasohibin-2 (VASH2) as its homologue having pro-angiogenic activity.Targeted Application(s)/Industry
We are planning to develop strategies of VASH1 potentiation and VASH2 inhibition. For VASH1 potentiation, we are planning to use recombinant VASH1 protein or search low molecular weight substances having VASH1 like activity. For VASH2 inhibition, we are succeeded in the development of neutralizing anti-human VASH2 monoclonal antibody.Researchers
Keywords
Prev
List
Next